Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy.

  title={Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy.},
  author={Yoshiyuki Hiki and Hiroko Odani and Masaaki Takahashi and Yoshinari Yasuda and A Nishimoto and Hitoo Iwase and Toru Shinzato and Y. Kobayashi and Kenji Maeda},
  journal={Kidney international},
  volume={59 3},
BACKGROUND The IgA1 molecule, which is predominantly deposited in glomeruli in IgA nephropathy (IgAN), is a unique serum glycoprotein because it has O-glycan side chains in its hinge region. Our study was conducted to investigate the O-glycan structure in the glomerular IgA1 in IgAN. METHODS The IgA1 was separated from 290 renal biopsy specimens of 278 IgAN patients and from four serum IgA1 samples (IgAN, 2; control, 2). The variety of O-glycan glycoform was determined by estimating the… 

Figures and Tables from this paper

O- and N-Glycosylation of Serum Immunoglobulin A is Associated with IgA Nephropathy and Glomerular Function.

High-resolution data suggest that IgA O- and N-glycopeptides are promising targets for future investigations on the pathophysiology of IgAN and as potential noninvasive biomarkers for disease prediction and deteriorating kidney function.

O-glycosylation of serum IgD in IgA nephropathy.

Observations show that abnormal IgA1 O-glycosylation in IgAN is not due to an inherent defect in glycosylations mechanisms but arises only at a later stage in B cell development and may be secondary to aberrant immunoregulation.

Clustered O-Glycans of IgA1

The results represent a new clinically relevant approach that requires ECD/electron transfer dissociation-type fragmentation to define the molecular events leading to pathogenesis of a chronic kidney disease and offers generally applicable principles for the analysis of clustered sites of O-glycosylation.

Identification of Distinct Glycoforms of IgA1 in Plasma from Patients with Immunoglobulin A (IgA) Nephropathy and Healthy Individuals*

It is demonstrated that undergalactosylation of O-glycans in IgA1 is not restricted to IgAN and suggested that in vivo inefficiency of T-synthase toward IgA 1 in a subpopulation of B or plasma cells, as well as overall elevation of IgA, may contribute to IgAn pathogenesis.

Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy

The results suggest that future analysis of IgA1 HR from IgAN patients and normal healthy controls should be feasible, and the first AI-ECD fragmentation on an individual IgA 1 O-glycopeptide from an IgA2 HR preparation that is reproducible for each IgA3 myeloma protein is reported.

Diagnostic Potential of Plasma IgA1 O-Glycans in Discriminating IgA Nephropathy From Other Glomerular Diseases and Healthy Participants

The amount of GalNAc and galactose in plasma IgA1 hinge region identified by glycoproteomics could be used as a diagnostic biomarker for IgA nephropathy and is promising for practical clinical applications.

IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy.

  • A. HorieY. Hiki K. Maeda
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2003

O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy.

It is demonstrated that IgA 1 O-glycosylation normally varies in different immune responses and that patients produce the full spectrum of IgA1 O- glycoforms.

Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy.

HAA-IgA binding is significantly increased in Japanese IgAN patients and the O-glycan structure of IgA1 hinge glycopeptides was shifted to smaller molecular weights in high HAA- IgA-binding IgAN Patients.



Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis.

This is the first study in which all of the predicted O-glycan forms of IgA1 have been analyzed simultaneously, and it is demonstrated that in IgAN, the IgA 1 Oglycan chains are truncated, with increased terminal GalNAc.

Reactivity of glomerular and serum IgA1 to jacalin in IgA nephropathy.

The results suggested that the increased reactivity of O-glycan(s) in the IgA1 hinge region to jacalin is due to an unusual glycosylation of serum IgA 1 in IgAN.

Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry.

The results obtained clearly showed a decrease of GalNAc, Gal, and sialic acid in IgAN compared with non-IgAN and normal controls, and those strongly suggested the possibility that the decreased galactosylation and sIALylation of the IgA1 hinge result in its glomerular deposition in IgAn.

Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

The results suggested the presence of a defect in the Gal and/or GalNAc residues in the IgA1 hinge glycopeptides in IgAN.

Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies.

The results suggest that the deficiency of Gal in the hinge region of IgA 1 molecules results in the generation of antigenic determinants containing GalNAc residues that are recognized by naturally occurring IgG and IgA1 antibodies.

Study of the relationship between sticky human serum IgA1 and its O-glycan glycoform.

Since the enzymatic removal of the N-glycan sugar chains did not induce the aggregation and exhibited no effect on the binding, the incomplete O-linked sugar chain on the hinge portion should be directly related to the sticky characteristics of the IgA1 molecule.

Galactosylation of N‐ and O‐linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy

The glycosylation of the IgA I molecule is investigated, as a potential non‐immunological abnormality which may contribute to its deposition in IgA nephropathy, and reduced terminal galactosylations of the hinge region O‐linked moieties was demonstrated.

Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG.

Increased reactivity of intact or de-sialylated serum IgA1 with N-acetylgalactosamine (GalNAc)-specific lectins, Helix aspersa (HAA) and Caragana arborescens (CAA) indicated that the Gal deficiency is in glycans located in the hinge region of IgA 1 molecules.

Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy.

Results indicated that the IgA1 molecules having the underglycosylated hinge glycopeptide played a certain role in the glomerular accumulation of IgA 1 in IgA nephropathy.

Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins.

The results indicated that the removal of carbohydrates from the IgA1 molecule resulted in noncovalent self-aggregation and a significant increase in adhesion to the ECM proteins.